Moderna = zero
placebo = 0.22%
Absolute Risk Reduction = 1.22%
Moderna = 0.08%
placebo = 1.33%
Absolute Risk Reduction = 1.25%
"... It must be noted that PCR tests are not fit for purpose and without Sanger sequencing we have no idea how many of these people actually had “COVID” vs another respiratory virus or something else.
... With 20 times more suspected COVID-19 than confirmed COVID-19,
and trials not designed to assess whether the vaccines can interrupt viral transmission, an analysis of severe disease irrespective of etiologic agent—namely, rates of hospitalizations, ICU cases, and deaths amongst trial participants—seems warranted,
and is the only way to assess the vaccines’ real ability to take the edge off the pandemic.
Approximately 5-6 symptoms listed as “side effects” are the same as COVID symptoms.
Pfizer/BioNtech only started counting “cases” one week after the second dose, and Moderna, 2 weeks after the second dose.
Therefore, if these (vaccine) side effects were labelled as “COVID” symptoms instead, even the paltry efficacy of about 1% would be relegated into the negative integers.
In others words, the injected group may have been sicker with “COVID” more than the placebo group.
There have been many critiques of the applicability of the limited data to the general populace, especially the vulnerable elderly.
An important analysis of this was done by Dr James Lyons-Weiler who discovered the general population is dying at a rate 6.3 times the rate of participants in the Moderna trial (including placebo and injection groups).
If Moderna’s on-vaccine death rate is so far below the national death rate and also simultaneously more than five times greater than Pfizer’s on-vaccine death rate,
then Pfizer’s study sample appears even less representative of the entire population. This, too, requires due consideration.”
An integral question as to whether Pfizer/BioNtech and Moderna recruited supermen and women for their trials, comes to mind.
The incidence of “severe” COVID in Placebo groups which scrutinizing the details, wasn’t necessarily severe presentation, is so low that trials of 30,000-40,000 lacked statistical power to determine reductions in hospitalizations and deaths, according to Tal Zaks, CMO Moderna.
Zaks is correct, the incidence of severe “COVID” was only 0.04% in Pfizer/BioNtech and 0.22% in Moderna.
Due to this very low attack rate of severe presentation in the population, the absolute risk reduction in severe presentation, even taking data at face value, is nominal.
Therefore, potential vaccine recipients must be informed that to reduce “severe” presentation, chances are over 99.5% that these synthetic gene therapies will not work."
